<DOC>
	<DOCNO>NCT02152761</DOCNO>
	<brief_summary>The purpose study ass bimagrumab safe effective patient muscle waste ( atrophy ) hip fracture surgery .</brief_summary>
	<brief_title>Study Efficacy Safety Bimagrumab Patients After Hip Fracture Surgery</brief_title>
	<detailed_description />
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antibodies , Blocking</mesh_term>
	<criteria>Must Xray confirm successful hip fracture repair ; must complete surgical wound healing ; ability walk specify distance without walk aid ; must weigh least 35 kg . Must history lower limb fracture past 6 month ; Must certain cardiovascular condition ; Must chronic active infection ( e.g . HIV , hepatitis B C , etc ) ; Must use highdose corticosteroid medication least 3 month past year ; Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>bimagrumab ,</keyword>
	<keyword>BYM338 ,</keyword>
	<keyword>hip fracture ,</keyword>
	<keyword>elderly ,</keyword>
	<keyword>control clinical trial ,</keyword>
	<keyword>randomize ,</keyword>
	<keyword>muscle wasting ( atrophy )</keyword>
</DOC>